Clinical Trial Update: Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating GSK's MMR vaccine Priorix in healthy children aged 12 to 18 months in Singapore.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• Priorix (Measles-Mumps-Rubella Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rubella, Mumps | Phase 4 | Status: COMPLETED